Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in Adults
Trial details
- Registry ID
- NCT06279871
- Phase
- Phase 3
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in AdultsNCT06279871 | Arcturus Therapeutics, Inc. | Phase 3 | Completed | 2024-10-09Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |